{"id":"clindamycin-phosphate-lotion-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Dryness or peeling"},{"rate":null,"effect":"Erythema or irritation"},{"rate":null,"effect":"Oiliness or folliculitis"},{"rate":null,"effect":"Contact dermatitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clindamycin is a lincosamide antibiotic that penetrates sebaceous follicles and inhibits bacterial protein synthesis, particularly effective against Propionibacterium acnes. When applied topically as a lotion, it reduces bacterial colonization and associated inflammatory responses in acne lesions. The phosphate salt formulation enhances skin penetration and stability.","oneSentence":"Clindamycin phosphate inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, reducing acne-causing bacteria and inflammation on the skin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:06:21.072Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris (topical treatment)"},{"name":"Bacterial skin infections"}]},"trialDetails":[{"nctId":"NCT06120140","phase":"PHASE2","title":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-02-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":300},{"nctId":"NCT04469075","phase":"PHASE2","title":"Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-07-09","conditions":"Glioblastoma, Recurrent Glioblastoma, Skin Toxicity","enrollment":48},{"nctId":"NCT05762484","phase":"NA","title":"Efficacy of Laser Hair Removal Therapy in HS","status":"NOT_YET_RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2023-04","conditions":"Hidradenitis Suppurativa, Acne Inversa","enrollment":58},{"nctId":"NCT03779360","phase":"NA","title":"Intradermal LPS and Antibiotics","status":"COMPLETED","sponsor":"Centre for Human Drug Research, Netherlands","startDate":"2018-10-12","conditions":"Inflammation; Skin","enrollment":32},{"nctId":"NCT03717506","phase":"PHASE3","title":"Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris","status":"COMPLETED","sponsor":"Balmoral Medical company","startDate":"2018-10-10","conditions":"Acne Vulgaris","enrollment":1236},{"nctId":"NCT03883269","phase":"PHASE4","title":"Anti-inflammatory Effects of Topical Erythromycin and Clindamycin in Acne Patients","status":"RECRUITING","sponsor":"Centre for Human Drug Research, Netherlands","startDate":"2018-03-20","conditions":"Acne Vulgaris","enrollment":30},{"nctId":"NCT03238469","phase":"NA","title":"Microwave Ablation in Mild Axillary Hidradenitis Suppurativa","status":"TERMINATED","sponsor":"M.B.A. van Doorn","startDate":"2017-09-01","conditions":"Hidradenitis Suppurativa, Acne Inversa","enrollment":9},{"nctId":"NCT00473083","phase":"PHASE2","title":"Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer","status":"COMPLETED","sponsor":"British Columbia Cancer Agency","startDate":"2009-01","conditions":"Rash","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Clindamycin Phosphate Lotion 1%","genericName":"Clindamycin Phosphate Lotion 1%","companyName":"Balmoral Medical company","companyId":"balmoral-medical-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clindamycin phosphate inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, reducing acne-causing bacteria and inflammation on the skin. Used for Acne vulgaris (topical treatment), Bacterial skin infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}